Država: Njemačka
Jezik: engleski
Izvor: HMA (Heads of Medicines Agencies)
pneumovirus 1.5 TCID50
Intervet Intenational BV
QI01AD01
Powder for nebuliser solution
Avian rhinotracheitis virus vaccine
Chicken
2010-04-02
Nobilis Rhino CV - Renew al (FR/V/0151/001/R/001) – SPC SUMMARY OF PRODUCT CHARACTERISTICS Nobilis Rhino CV - Renew al (FR/V/0151/001/R/001) – SPC 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobilis Rhino CV ES: Nobilis RT 11/94; IT: Nobilis ® RTCV 1194; AT, DE: Nobilis Rhino 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Per dose min. 10 1.5 TCID 50 * and max. 10 3.7 TCID 50 of live attenuated avian rhinotracheitis virus strain 11/94. For a list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate for suspension for oculonasal or spray application. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Chicken. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For broilers, future layers and breeders from one day of age. _ _ _Broilers, future layers and breeders _ Active immunisation in order to reduce the frequency and the severity of clinical signs due to infection with avian rhinotracheitis virus (avian metapneumovirus). The onset of immunity is 3 weeks and the duration of immunity is 16 weeks post-vaccination. _Future layers and breeders _ Priming with Nobilis Rhino CV, followed by a second vaccination with an inactivated vaccine containing the avian rhinotracheitis virus strain But1#8544 before the onset of lay results in a reduction of the clinical signs including egg drop, caused by infection with avian rhinotracheitis virus. Protective immunity is maintained for the normal laying period. 4.3 CONTRAINDICATIONS None. 4.4 SPECIAL WARNINGS None. * Tissue Culture Infective Dose 50% Nobilis Rh Pročitajte cijeli dokument